Gilead is very confident on the successful commercial launch of Axi-Cel.
Gilead Pivots to Cell Therapy; Cowen’s Phil Nadeau Weighs in
Genocea Biosciences Inc (NASDAQ:GNCA) shares were plummeting almost 15% yesterday after the biotech firm and are another 5% dive today after a lackluster …
Dynavax Technologies Corporation (NASDAQ:DVAX) shares are skyrocketing over 70% after the FDA VRBPAC panel voted 12-1 with 3 abstentions that the safety to …
The FDA Vaccines & Related Biological Products Advisory Committee (VRBPAC) is meeting today to discuss the safety and efficacy of Dynavax Technologies Corporation’s (NASDAQ:DVAX) experimental …
Yesterday at the 9th International Aids Society (IAS) conference on HIV Science in Paris, Gilead Sciences, Inc. (NASDAQ:GILD) made crucial strides forward.
Cowen analyst Phil Nadeau is out with a bullish note on shares of Genocea Biosciences Inc (NASDAQ:GNCA), reiterating an Outperform rating with a $40 price …
Third party sources are saying Gilead Sciences, Inc. (NASDAQ:GILD) domestic Wholesale Acquisition Costs (WACs) of various products have seen a price boost, to …
Gilead Sciences, Inc. (NASDAQ:GILD) impressed Cowen analyst Phil Nadeau with its successful four Phase III trials evaluating a dose combination of the biotech …
Gilead Sciences, Inc. (NASDAQ:GILD) hepatitis C franchise will again be in the spotlight when the pharmaceutical giant reports first-quarter earnings, scheduled for May 2, after …
